Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Capri Holdings Ltd (CPRI) Price & Performance

AstraZeneca plcTrade
Capri Holdings LtdTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Capri Holdings Ltd — how do they compare? AstraZeneca plc trades at $157.44 (market cap $248.14B), while Capri Holdings Ltd trades at $15.39 (market cap $1.75B). The key difference: AstraZeneca plc is far larger — about 141.8× Capri Holdings Ltd's market cap, and AstraZeneca plc pays a 2.01% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals.

AZNCPRI
Market Cap
$248.14B$1.75B
Sector
HealthConsumer Staples
52-Week High
$209.48$27.66
52-Week Low
$147.06$14.98
Enterprise Value
$275.41B$3.03B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.

The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.

Capri Holdings Ltd

CPRI trades at $15.43, down 65% over five years but showing recent earnings momentum with three consecutive quarterly beats. The stock faces bearish technical signals with moving averages indicating downward pressure, while fundamentals reveal declining revenue from $5.7B in 2022 to $4.4B in 2025 and a significant net loss of -$1.18B. Analyst consensus sits at $19.60 with mixed ratings (44% Buy, 52% Hold), reflecting cautious optimism about the company's turnaround strategy post-Versace sale.

The investment case hinges on CPRI's ability to stabilize Michael Kors and grow Jimmy Choo profitability, but risks include ongoing revenue declines, luxury market softness, and high debt levels. With the current price near 52-week lows and 27% upside to consensus target, the stock offers potential for recovery if management executes its revamp plans successfully, though macroeconomic headwinds and brand challenges remain significant concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Capri Holdings Ltd

Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.

Read more on CPRI